Viewing entries tagged
News

ImevaX strengthens executive management team

Munich (Germany), September 16, 2015: ImevaX GmbH, a specialist in rapid diagnostic tests and developing vaccines against pathogens of chronic infectious diseases, especially H. pylori infections, announced today the appointment of Dr James Neil Phillips as Chief Executive.

ImevaX secures EUR 1.25 Million in Series A-2 Financing

Munich (Germany): ImevaX GmbH, a specialist in rapid diagnostic tests and vaccines against pathogens of chronic infectious diseases, announces today the completion of a EUR 1.25 million Series A-2 financing round. The round was led by Wellington Partners. Co-lead investors were BioMedPartners with their BioMedInvest-II LP fund and Santo Venture Capital. ImevaX is a 2014 spin-out from the Technische Universität München (TUM) and has been awarded a EUR 5.9 million financing from the GO-Bio Phase II program of the Federal Ministry of Education and Research (BMBF).

ImevaX secures EUR 6.4 Million in Series A (option to invest) Financing

Munich (Germany): ImevaX GmbH, a specialist in rapid diagnostic tests and vaccines against pathogens of chronic infectious diseases, announces today the completion of a EUR 6.4 million Series A (option to invest) financing round. The round was led by Wellington Partners. Co-lead investors were BioMedPartners with their BioMedInvest-II LP fund, Santo Venture Capital, KfW and EMBL Ventures. ImevaX is a 2014 spin-out from the Technische Universität München (TUM) and has been awarded a EUR 5.9 million financing from the GO-Bio Phase II program of the Federal Ministry of Education and Research (BMBF).